SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on speculation that SELLASs Phase 3 REGAL AML trial is nearing its final event trigger and subsequent topline analysis, with traders reacting to CEO commentary and favorable remarks from pharmaceutical-industry professionals. The community remains sharply divided: bulls view the prolonged survival and outside commentary as supportive, while bears question the trial design, delayed event timing, and likelihood of a successful readout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Preliminary second-quarter results showing sharply improved operating profitability despite lower revenue, together with an amended convertible-note exchange that limits stock issuance and shifts the remainder to cash, are driving attention. Traders are divided between viewing the developments as evidence of improving fundamentals and reduced dilution risk, and focusing on revenue declines, management concerns, and unusual warrant activity that has fueled speculative squeeze discussion.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of its city WiFi into Helium-powered carrier coverage is driving attention, with traders viewing the deployment and broader carrier-offload use case as evidence of real-world DePIN adoption. Bullish commenters expect continued momentum, while skeptics question token dilution, hotspot profitability, and whether network usage will translate into value for HNT holders.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Anticipation of broader federal marijuana rescheduling to Schedule III, including an upcoming administrative-law recommendation, is driving attention as traders expect reduced tax burdens and improved institutional access for U.S. cannabis operators. The community remains largely bullish on Trulieves positioning and NYSE listing, while others warn that the catalyst is not yet finalized and cite profit-taking, overbought conditions, and post-earnings concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Strong Phase 3 data for CAN-2409 in localized prostate cancer, along with anticipation of ASTRO findings and a planned Q4 BLA submission, is driving bullish attention. Traders see potential regulatory and pharmaceutical-partnership upside, while skeptics point to dilution risk, the unfiled BLA, profit-taking, and broader biotech momentumincluding enthusiasm around cancer-vaccine developmentsas competing factors.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Reports of renewed U.S.-Iran hostilities, tanker attacks, and severely disrupted Strait of Hormuz flows are driving attention to USO, with traders debating whether the supply shock will lift crude prices. The Venezuela oil agreement and possible diplomatic reopening are viewed by bears as longer-term supply relief, while bulls argue infrastructure limits mean they will not quickly offset the disruption.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Escalating Iran and Strait of Hormuz tensions, along with volatile oil prices, are driving attention to Carnival as traders weigh higher fuel costs and travel disruption risks. The community is divided between bearish short-term views tied to geopolitical headlines and bullish investors citing resilient bookings, debt reduction, buybacks, dividends, and perceived undervaluation.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Upcoming quarterly earnings are the dominant catalyst, with traders focused on whether Broadcoms AI custom-chip and networking demand will support stronger guidance. Bulls expect a beat and continued momentum from OpenAI and hyperscaler projects, while bears argue expectations are already elevated and remain concerned about debt, potential Google-related share loss, and another post-earnings selloff.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Positive Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, including substantial triglyceride reductions and fewer acute pancreatitis events, are driving attention and expectations for a broader regulatory filing. Traders are broadly bullish on REDEMPLOs commercial potential and Arrowheads RNAi platform, although some debate the valuation, competition from Ionis, and the stocks volatile sell-the-news trading.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Canadian government funding for Xanadus quantum-manufacturing Project OPTIMISM is driving attention, while traders debate whether additional federal and Ontario support will materialize. The community is split between viewing the backing as validation of Xanadus photonic technology and warning that heavy cash burn, limited revenue, and potential dilution could offset the benefit.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares Rise as Biotech Pivots Toward AI-Driven Pharmaceutical Automation

Pharmaceutical manufacturing is one of the most heavily regulated industries in the world. Every batch, every deviation, and every cleaning record must be documented and defensible under audit. This process has traditionally been manual, slow, and expensive. Companies capable of automating these workflows with AI stand to save significant time while reducing compliance risk. Today, one clinical-stage biotech announced a strategic deal to bring that automation to the physical factory floor.&nbsp;Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on the ...

Micro-Cap Stuns Market with Billion-Dollar Pipeline Valuation

It&#8217;s not often that a micro-cap company with a market value of around $40 million announces a third-party valuation of its drug development pipeline at $1.7 billion, 45% of which it owns. But that&#8217;s exactly what was revealed in a press release this morning. As expected, the stock reacted swiftly and rallied on the news.As mentioned, shares of Oncotelic Therapeutics <a href="https://www.allpennystocks.com/stockquote/OTLC" target="_blank">(OTCQB: OTLC)</a> are surging on news that the company announced a major milestone after its joint venture partner, GMP Bio, completed an independent third-party valuation of its drug development pipeline. The assessment, performed by Frost &amp; Sullivan (Hong Kong), values the pipeline at roughly $1.7 billion, translating to an estimated $765 million potential value for Oncotelic based on its 45% ownership stake. The company noted that this figure is forward-looking and non-binding, and it does not reflect fair value under U.S. GAAP. To support upcoming financial disclosures, a separate ASC-compliant valuation is already underway. If that analysis indicates a materially higher carrying value, Oncotelic may adjust future financial statements to reflect its increased minority interest, potentially boosting total assets and shareholder equity, pending the outcome of the review and applicable accounting standards.The joint venture has made significant progress across its therapeutic programs, including moving OT-101 into a Phase 3 PDAC trial and multiple Phase 2 combination studies. Meanwhile, GMP Bio is actively expanding its Deciparticle&#8482; nanomedicine platform, with several candidates advancing toward clinical development. Its San Diego GMP-licensed manufacturing facility is now fully operational and ready to support upcoming trials. Looking ahead, the JV is exploring a possible IPO on the Hong Kong Stock Exchange targeted for late 2026. While market conditions and regulatory approval will ultimately dictate the timing, Oncotelic views the strong pipeline valuation as a key indicator of the strategic value behind the potential offering.&#8220;This represents one of the most significant milestones in Oncotelic&#8217;s history,&#8221; said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics. &#8220;The independent valuation recognizes the multi-year scientific and clinical progress achieved through our GMP Bio joint venture and affirms the long-term potential of OT-101 and our Deciparticle&#8482; nanomedicine platform.&#8221;Shares of OTLC are currently trading up 26.15% at $0.09524 in mid-morning trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4012/micro-cap-stuns-market-with-billion-dollar-pipeline-valuation'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

Oncotelic Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.0312
Prev Close	$0.0312
Open	$0.0315
Dividend Yield	0.00%
50-Day Moving Average	$0.0388
Beta	-0.07
Avg. Volume	319,353.00
PE Ratio	0.06

52-Week High	$0.11
52-Week Low	$0.015
Market Capitalization	$14.27M
EPS (Annual)	$0.592
Price to Book	0.05
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info